期刊
CLINICAL & TRANSLATIONAL IMMUNOLOGY
卷 2, 期 -, 页码 -出版社
WILEY
DOI: 10.1038/cti.2013.5
关键词
melanoma; immunity; immunotherapy; checkpoint blockade; tumor-infiltrating lymphocytes
类别
资金
- Bristol-Myers Squibb
The strategy of immune modulation for the treatment of cancer is being refined with the introduction of multiple new therapeutic agents into the clinic. Melanoma is a disease where many of these agents have demonstrated efficacy. The mechanisms of action of these agents exploit the counter-regulatory mechanisms of the immune response. However, these agents are also associated with immune-related adverse events (IRAEs), which represent tissue-specific inflammatory responses. These IRAEs highlight the delicate balance of immunologic homeostasis and, with some interventions, may occur more frequently in patients who sustain a therapeutic response. This review will discuss melanoma immunogenicity and immunotherapy. Furthermore, the spectrum and distinction between a reversible immune adverse event and autoimmunity will be highlighted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据